EP1252158B1 — Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
Assigned to Pfizer Products Inc · Expires 2005-04-20 · 21y expired
What this patent protects
Compounds useful as inhibitors of PDE4 in the treatment of diseas s regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of Formula (1.0.0.). In said formula R?5 and R6¿ are taken together …
USPTO Abstract
Compounds useful as inhibitors of PDE4 in the treatment of diseas s regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of Formula (1.0.0.). In said formula R?5 and R6¿ are taken together to form a moiety of partial Formulas (1.1.1) through (1.1.5) or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
- Otezla (APREMILAST) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.